Author Archive: AZBio

Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer

Posted on by
  • FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2
  • Metastatic prostate cancer has a 5-year survival rate of less than 30%3; mCRPC patients who progress on multiple lines of therapy have limited treatment options 
  • FDA approval was based on pivotal Phase III VISION trial, where patients with pre-treated PSMA-positive mCRPC who received Pluvicto plus standard of care had a statistically significant reduction in risk of death1; both alternate primary endpoints of overall survival and radiographic progression free survival were met1
  • Novartis is committed to reimagining medicine in prostate cancer with targeted radioligand therapy – a type of precision cancer treatment combining a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle)
  • Two pivotal Phase III studies evaluating Pluvicto in earlier lines of treatment for metastatic prostate cancer are underway, with a goal to move into earlier stages of disease

Continue reading→

HTG Releases Proof-of-Approach Whitepaper Establishing Utility of Transcriptome-Informed Approach to Drug Discovery

Posted on by

TUCSON, Ariz., March 31, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, has released its first proof-of-approach white paper (the “White Paper”), establishing the utility of its novel approach to drug discovery utilizing its proprietary platform.Continue reading→

Third Cohort of Mayo Clinic and Arizona State University MedTech Accelerator Commences

Posted on by

TEMPE, Ariz. — More than two years into a global pandemic, the clear need for innovative medical breakthroughs has never been more obvious. The Mayo Clinic and Arizona State University (ASU) MedTech Accelerator, a flagship program of the Mayo Clinic and ASU Alliance for Health Care, was designed to help empower medical startups to better navigate challenges while bringing forth life-changing health innovations. The third cohort of this program launched on March 28.Continue reading→

HB2039 Health; Innovation; Trust Fund

Posted on by

On March 29, 2022, Arizona’s  Senate Appropriations Committee voted unanimously to give a Do Pass as Amended recommendation for HB2039.  The next step in the process is review by the Senate Rules Committee.

If HB2039 successfully completes the legislative process and is signed into law by the Governor, it will establish the statutory framework for the Arizona Health Innovation Trust Fund within the Arizona State Treasurer’s Office with the State Treasurer as Trustee. Continue reading→

Life365 Partners with Microsoft Cloud for Healthcare to Empower Providers and Payors to Transition Care to Low-Cost Settings – Home

Posted on by

Scottsdale, AZ, March 22, 2022— Life365, a Microsoft Partner and leading Virtual Care and Remote Patient Monitoring (RPM) platform, announced today the integration into Microsoft Cloud for Healthcare, empowering Providers and Payors to connect and scale to larger patient populations in low-cost settings, typically at home.Continue reading→

HTG Molecular Diagnostics Announces $7.5 Million Private Placement

Posted on by
 
TUCSON, Ariz., March 18, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has entered into a definitive securities purchase agreement to sell securities in a private placement with a leading healthcare investor. The gross proceeds to HTG from the private placement, before deducting the placement agent fees and other estimated fees and expenses related to the private placement, are expected to be approximately $7.5 million. HTG intends to use the net proceeds from the private placement for working capital and general corporate purposes.   

Continue reading→

Nearly 100 Organizations and Experts Urge HHS Secretary Xavier Becerra to Reject Xtandi March-In Petition

Posted on by

WASHINGTON, D.C. (March 17) — In a letter transmitted today, the Bayh-Dole Coalition and nearly 100 prominent academic and private sector innovation experts and organizations, public policy associations, and legal scholars urged U.S. Department of Health and Human Services Secretary Xavier Becerra to reject the latest march-in petition on prostate cancer drug Xtandi.Continue reading→